ATLANTA, Dec. 10, 2007 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that results from two preclinical studies indicating that the Company’s proprietary product candidates improve the therapy of cancer compared to certain established treatments. These results were presented at the 49th annual meeting of ASH in Atlanta, GA.
